Efficace trattamento con axicabtagene ciloleucel di una paziente con linfoma diffuso a grandi cellule B recidivato precocemente

Refractoriness and early relapse after first-line therapy are two high-risk conditions for patients with diffuse large B-cell lymphoma (DLBCL). Nowadays, axicabtagene ciloleucel (axi-cel) is the therapeutic strategy to adopt in these clinical conditions, considering the results obtained in terms of overall survival and progression free survival in the ZUMA-7 trial. In the clinical case here reported, a female patient with an early relapsed triple expressor DLBCL was successfully treated with axi-cel, obtaining the complete remission at one month from therapy. Similarly, the adverse events onset after axi-cel were successfully and quickly treated.